Research

Mixed

GLP-1 receptor agonists, particularly semaglutide and tirzepatide, are associated with an increased risk of non-scarring hair loss (telogen effluvium and androgenetic alopecia), primarily driven by rapid weight loss and nutritional deficits rather than direct drug toxicity.

If you are using semaglutide or tirzepatide and notice hair shedding, it is likely due to rapid weight loss or nutritional deficits rather than permanent drug damage. Ensure adequate protein and micronutrient intake (iron, zinc) and consider slowing dose escalation. The risk is highest with these specific drugs and in females, but often stabilizes as weight loss plateaus.

ModerateSupportsMEDIUM confidence
Accumulating evidence from pharmacovigilance databases and clinical cohorts suggests an increased risk of hair loss with certain GLP-1 RAs, particularly semaglutide and tirzepatide... Rapid weight loss emerged as a potential contributor, particularly for telogen effluvium.
Aditya K. Gupta et al. · Science Progress · 2026

Why this rating

Evidence is largely from pharmacovigilance and retrospective cohorts; randomized trials show modest but consistent signals, but causality is not fully established.

Source

GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling

Aditya K. Gupta et al. · Science Progress · 2026

DOI 10.1177/00368504261444578

systematic_reviewCited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →